Inactive Instrument

Highlights VG Life Sciences Inc. Other OTC

Equities

Feelux Co., Ltd completed the acquisition of 23.09% stake in VG Life Sciences Inc. from Alpha Holdings, Inc. and others for KRW 17.3 billion.	22/11/18	CI
Alpha Holdings, Inc. cancelled an additional stake of 12.49% in VG Life Sciences Inc from TJU Asset Management, LLC and Penn Life Science, LLC.	11/10/17	CI
Alpha Holdings, Inc. agreed to acquire an additional stake of 12.49% in VG Life Sciences Inc from TJU Asset Management, LLC and Penn Life Science, LLC for KRW 4.7 billion.	11/10/16	CI
VG Life Sciences Inc. Progress Update Phase I Cancer Study	04/09/14	CI
VG Life Sciences Inc. Reports Clinical Outcomes in Phase I Cancer Study	14/03/14	CI
VG Life Sciences, Inc. Announces Update on Phase I Cancer Study	13/12/13	CI
VG Life Sciences Inc. Reports Positive Safety Results from Second Cohort Enrollment in Solid Tumor Clinical Trial	04/04/13	CI
VG Life Sciences Inc. Completes First Stage of its Phase I Trial to Treat Ovarian Cancer	31/01/13	CI
VG Life Sciences Inc. Expands Ovarian Cancer Trial	14/01/13	CI
Viral Genetics Inc. Submits Pre-IND Document for Lyme Disease Drug Candidate to United States Food and Drug Administration	07/03/12	CI

No results for this search